Drug Price Trends for THYROID

Average Pharmacy Cost for THYROID

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
THYROID 15 MG TABLET	69680-0165-00	0.52850	EACH	2025-03-19
THYROID 30 MG TABLET	62559-0741-01	0.61672	EACH	2025-03-19
THYROID 15 MG TABLET	62559-0740-01	0.52850	EACH	2025-03-19
THYROID 90 MG TABLET	69680-0168-00	1.06353	EACH	2025-03-19
THYROID 120 MG TABLET	62559-0744-01	1.21620	EACH	2025-03-19

Thyroid Gland Disorder Treatment Market: Analysis and Price Projections

Introduction to Thyroid Gland Disorders

Thyroid gland disorders, including hypothyroidism and hyperthyroidism, are significant health concerns affecting a large population globally. These conditions require continuous medical management, driving the demand for thyroid medications.

Market Size and Growth Projections

The global thyroid gland disorder treatment market is anticipated to experience steady growth over the coming years.

• By 2025, the market is expected to reach USD 2.6 billion, growing at a CAGR of 3.2% from 2014 to 2025[1].
• Another report indicates that the market will grow from $2.4 billion in 2023 to $2.75 billion by 2028, at a CAGR of 2.8%[2].
• Allied Market Research projects the market to reach $2,771 million by 2025, with a CAGR of 3.8% from 2018 to 2025[4].

Key Drivers of Market Growth

Several factors are driving the growth of the thyroid gland disorder treatment market:

• Increasing Prevalence of Thyroid Diseases: The rise in thyroid disorders such as hypothyroidism and hyperthyroidism is a major driver. Hypothyroidism, in particular, is a leading cause of hospitalization in the U.S.[1].
• Awareness and Education: Growing awareness among healthcare professionals and patients about disease management is another significant factor. Organizations like the British Thyroid Foundation, the American Thyroid Association (ATA), and the Thyroid Foundation of Canada are actively involved in spreading awareness[1].
• Advancements in Drug Development: Continuous advancements in drug development, including the introduction of new oral anti-thyroid medications, are contributing to market growth[1].
• Healthcare Infrastructure and Expenditure: Sophisticated healthcare infrastructure and high healthcare expenditure, particularly in regions like North America, are also driving the market[1][4].

Market Segmentation

The thyroid gland disorder treatment market is segmented based on several criteria:

By Indication

• Hypothyroidism: This segment held the dominant revenue share in 2016 and is expected to maintain its position throughout the forecast period[1].
• Hyperthyroidism: Expected to witness steady growth due to the increasing incidence of Graves' disease[1].

By Route of Administration

• Oral: The most preferred route of administration due to its convenience and simplicity, which improves patient compliance[1].
• Intravenous: Less common but still a viable option in certain cases.
• Others: Includes other routes of administration that are less frequently used[1].

By Distribution Channel

• Wholesalers/Distributors: Accounted for the largest revenue share in 2016 due to increasing spending on outpatient prescription drugs and overall healthcare expenditure[1].
• Retail Chain: Significant but less dominant compared to wholesalers.
• Online Distribution: Expected to witness lucrative growth in the coming years[1].
• Others: Includes other distribution channels such as hospitals and clinics.

By Region

• North America: The U.S. thyroid gland disorder treatment market is anticipated to exceed USD 1.03 billion by 2025, driven by sophisticated healthcare infrastructure and high healthcare expenditure[1].
• Asia-Pacific: Countries like India and China are expected to observe remarkable growth during the forecast period[1].
• Europe: Significant market share, with countries like the U.K. and Germany contributing substantially[1].

Injectable Thyroid Drug Market

The injectable thyroid drug market is a subset of the broader thyroid gland disorder treatment market and is also experiencing growth:

• The global injectable thyroid drug market is projected to increase from US$ 439.65 million in 2024 to US$ 765.4 million by 2034, at a CAGR of 5.7%[3].
• The United States is expected to exhibit a CAGR of 4.2% during this period, driven by a sophisticated healthcare system and high demand for thyroid medications[3].

Regulatory Framework and Quality Standards

The regulatory framework, particularly in the United States, plays a crucial role in ensuring the safety, efficacy, and quality of thyroid medications. The FDA oversees these standards, which instills confidence in both domestic and international markets[3].

Patient-Centric Care and Technological Advancements

Major trends in the forecast period include:

• Thyroid Surgery and Radioactive Iodine Alternatives: These alternatives are becoming more popular due to their effectiveness and reduced side effects[2].
• Telemedicine and Remote Monitoring: Patient-centric care models, including telemedicine and remote monitoring, are gaining traction, enhancing patient compliance and outcomes[2].

Economic and Demographic Factors

Global economic conditions, patient demographics, and healthcare expenditure are significant factors influencing the market growth. An aging population, especially in North America, is contributing to the increased demand for thyroid medications[2][5].

Thyroid Cancer Drugs Market

While the focus is on general thyroid gland disorders, the thyroid cancer drugs market is also worth noting:

• The global thyroid cancer drugs market was valued at USD 1.2 billion in 2022 and is projected to reach USD 4.3 billion by 2031, with a CAGR of 14.6% during the forecast period (2023-2031)[5].
• The rise in neuroendocrine tumor cases and the presence of top pharma and biotech companies in North America are driving this market[5].

Key Takeaways

• The global thyroid gland disorder treatment market is expected to reach USD 2.6 billion by 2025, driven by increasing prevalence of thyroid diseases and advancements in drug development.
• Hypothyroidism dominates the market, with oral administration being the most preferred route.
• North America, particularly the U.S., is a significant market due to its sophisticated healthcare infrastructure and high healthcare expenditure.
• The injectable thyroid drug market is growing at a CAGR of 5.7% from 2024 to 2034.
• Patient-centric care models, including telemedicine and remote monitoring, are becoming more prevalent.

FAQs

Q: What is the projected size of the global thyroid gland disorder treatment market by 2025? A: The global thyroid gland disorder treatment market is expected to reach USD 2.6 billion by 2025[1].

Q: Which segment dominates the thyroid gland disorder treatment market? A: Hypothyroidism dominates the market in terms of revenue share[1].

Q: What is the most preferred route of administration for thyroid medications? A: The oral route is the most preferred due to its convenience and simplicity[1].

Q: Which region is expected to witness the highest growth in the thyroid gland disorder treatment market? A: Asia-Pacific, particularly countries like India and China, are expected to observe remarkable growth[1].

Q: How is the injectable thyroid drug market expected to grow from 2024 to 2034? A: The injectable thyroid drug market is projected to grow at a CAGR of 5.7% from 2024 to 2034, reaching USD 765.4 million by 2034[3].

Sources

1. Grand View Research: "Thyroid Gland Disorder Treatment Market Worth $2.6 Billion By 2025"[1]
2. The Business Research Company: "Anti-Thyroid Drugs Global Market Report 2024"[2]
3. Future Market Insights: "Injectable Thyroid Drug Market Share, Trend & Forecast 2034"[3]
4. Allied Market Research: "Thyroid Gland Disorder Treatment Market is to Reach $2771 Mn"[4]
5. Straits Research: "Thyroid Cancer Drugs Market Size to Jump at US$4.3 billion by 2031"[5]